Public Screening Programs in Uzbekistan and Northeast India

NZX/ASX Announcement 14 August 2025 Public Screening Programs in Uzbekistan and Northeast India • Uzbekistan Memorandum of Understanding (MOU) signed to conduct a 500-patient pilot screening program using TruScreen’s unique, real-time, AI enabled screening device. • The program assesses “the implementation of TruScreen in the most effective way to prevent cervical cancer” and to “develop a National Cervical Cancer Screening program for Uzbekistan”. Uzbekistan has 11 million women of screening age* • TruScreen to be used in a remote screening program at Leh Town, Jammu Kashmir, Northeast India • TruScreen installed into key ASEAN reference centre at Singapore’s leading gynaecological clinic of Dr Quek Swee Cheong, Gleneagles Hospital, Singapore TruScreen Group Limited (NZX/ASX: TRU), (“TruScreen” or “the Company”), a global leader in AI-enabled cervical cancer screening, is pleased to provide an update on the implementation of its strategy to engage with Ministries of Health, Non-Government Organizations (NGO’s) and private foundations funding public screening programs in emerging markets. Uzbekistan MOU signed to conduct a 500-patient pilot program in Karakalpakstan, Uzbekistan Senator & Professor Aral Ataniyazova, Deputy Chair of the Committee for Health Science and Education and a Senator in the Uzbek Government has signed an MOU with TruScreen to conduct the 500-patient pilot project in Karakalpakstan. The program, entitled “Pilot Project for the use of TruScreen in Uzbekistan” will commence in September and be completed in October 2025. The program will be conducted by Karakalpak Centre for Reproductive Health and Environment ("Perzent"), and supervised by Senator & Professor Ataniyazova, with collaborations from, • Dr Klara Yadgorava, Project Chair. Dr Yadgarova is a World Health Organization (WHO) nation consultant for Uzbekistan and consultant for Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH for Uzbekistan projects https://www.giz.de/en/html/index.html • Professor Asamidin Kamilov Professor Kamilov was the Deputy Health Minister in Uzbekistan for over 13 years. The objectives of the program are: 1. To assess cervical screening options for the women of Uzbekistan and the implementation of TruScreen in the most effective way to prevent cervical cancer, the accuracy, reliability and operational requirements of TruScreen compared to Pap smear in detecting early cancerous changes in the cervix. 2. To develop a National Cervical Cancer Screening program for Uzbekistan In addition to the signing of the MOU, TruScreen CEO Martin Dillon met with key Heads of Departments at Uzbekistan’s Ministry of Digital Technologies (Uzinfocom) - integrator for creation and support of state information systems in Uzbekistan - to discuss the pathway for integrating TruScreen into their planned national Health Information System. These developments have followed quickly after TruScreen’s regulatory approval by the National Pharmaceutical Safety Committee in Uzbekistan in June 2025. Uzbekistan has over 11 million women of screening age* and is also a regional healthcare reference site for neighbouring Central Asian “Stans” nations. TruScreen is delighted to be able to support the country’s screening goals and patient outcomes. TruScreen Selected for Public Screening Program in Northeast India, and opened a reference site at Gleneagles Hospital in Singapore TruScreen has been selected for use in a public screening program in Leh Town, Ladakh, Jammu Kashmir, India. The program will screen 1,800 women in remote mountain villages in Northeast India. The program is organised and conducted by a volunteer gynaecological team led by Dr Quek Swee Cheong, who is a board member of the International Federation of Colposcopy and Cervical Pathology. Dr. Quek is past President and a current council member of the Society of Colposcopy and Cervical Pathology of Singapore. A TruScreen medical device was also installed in the private clinic of Dr. Quek at the Parkway Gynaecology Screening & Treatment Centre, Gleneagles Hospital, Singapore. Dr Quek was one of the key clinical contributors to the development of the unique TruScreen algorithm, and his clinic will be a key reference centre for the acceptance of TruScreen into the ASEAN market. TruScreen CEO, Martin Dillon commented: “The signing of the Memorandum of Understanding by Senator Ataniyazova so quickly following product registration demonstrates the commitment of the Uzbekistan government to the assessment and selection process for TruScreen as a technology for a national cervical cancer screening program. In addition, this program engages TruScreen with not just the Uzbekistan Government, but with the in-country representative of both the World Health Organisation and the major German Foundation, GIZ. The selection of TruScreen for the Leh Town project by the internationally influential Dr Quek Swee Cheong will continue TruScreen’s growth into the public screening sector. These achievements consolidate the global recognition of TruScreen by governments, NGO’s and Foundations as a solution to the problem of conducting public screening programs in emerging markets.” This announcement has been approved by the Board. *CIA World Factbook women aged 15-64 = 95,961,293 Ends For more information, visit www.truscreen.com or contact: Martin Dillon Chief Executive Officer martindillon@truscreen.com Guy Robertson Chief Financial Officer guyrobertson@truscreen.com